KFO 129:  Mechanismen der Resistenzentwicklung und Optimierung antiviraler Strategien bei Hepatitis C Virusinfektion unter Einbeziehung integrativer Modelle der Biomathematik und Bioinformatik

• Fachliche Zuordnung: Medizin
• Förderung: Förderung von 2005 bis 2010
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 5397647

• Erstellungsjahr: 2013

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. Journal of Infectious Diseases, Vol. 192. 2005, Issue 10, pp. 1710–1719.
  C. Sarrazin, U. Mihm, E. Herrmann, C. Welsch, M. Albrecht, et al., T. Lengauer, S. Zeuzem
  
• Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antiviral Therapy, Vol. 11. 2006, Issue 4, pp. 507-519.
  U. Mihm, N. Grigorian, C. Welsch, E. Herrmann, B. Kronenberger, et al., W.P. Hofmann, M. Albrecht, T. Lengauer, S. Zeuzem, C. Sarrazin
  
• Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antiviral Therapy, Vol. 12. 2007, Issue 5, pp. 779-787.
  B. Kronenberger, S. Zeuzem, C. Sarrazin, U. Mihm, W.P. Hofmann, E. Herrmann et al.
  
• Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology, Vol. 132. 2007, Issue 3, pp. 921-930.
  W.P. Hofmann, A. Polta., E. Herrmann, U. Mihm, B. Kronenberger, et al., S. Zeuzem, C. Sarrazin
  
• Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases. Journal of Viral Hepatitis, Vol. 14. 2007, Issue 7, pp. 484-491.
  W.P. Hofmann, B. Fernandez, E. Herrmann, C. Welsch, U. Mihm, B. Kronenberger, et al., S. Zeuzem, C. Sarrazin
  
• Structural and functional comparison of the non-structural protein 4B in flaviviridae. Journal of Molecular Graphics and Modelling, Vol. 26. 2007, Issue 2, pp. 546-557.
  C. Welsch, M. Albrecht, E. Herrmann, M.W. Welker, C. Sarrazin, A. Scheidig, T. Lengauer, S. Zeuzem, et al.
  
• Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Journal of Hepatology, Vol. 50. 2009, Issue 1, pp. 49-58.
  U. Mihm, et al., C. Welsch, E. Herrmann, W.P. Hofmann, T. Lengauer, S. Zeuzem, C. Sarrazin, et al.
  
• Comparison of Envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. Journal of Viral Hepatitis, Vol. 18. 2011, Issue 3, pp. 181-192.
  M.W. Welker, C. Welsch, W.P. Hofmann, E. Herrmann, R.W. Hartmann, S. Zeuzem, C. Sarrazin, B. Kronenberger, et al.
  
• Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antiviral Therapy, Vol. 16. 2011, Issue 5, pp. 695-704.
  W.P. Hofmann, T.L. Chung, C. Osbahr, S. Susser, U. Mihm, C. Welsch, J. Lötsch, C. Sarrazin, S. Zeuzem, E. Herrmann, et al.
  
• Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenetics and Genomics, Vol. 21. 2011, Issue 5, pp. 289-296.
  A. Doehring, W.P. Hofmann, C. Schlecker, S. Zeuzem, C. Sarrazin, E. Herrmann, G. Geißlinger, J. Lötsch, et al.